WOBURN, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) — Biofrontera Inc. (Nasdaq:BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three and nine months ended September 30, 2025 after the close of the U.S. financial markets on Wednesday, November 12, 2025. The company will host a conference call on Thursday, November 13 at 10:00am Eastern Time to discuss those results, provide a business update and answer questions.
Conference Call and Webcast Information
| Event: | Biofrontera Inc. Third Quarter 2025 Financial Results and Business Update Conference Call |
| Date: | Thursday, November 13, 2025 |
| Time: | 10:00am ET |
| Conference Call: |
1-877-877-1275 (U.S.) 1-412-858-5202 (international) |
| Webcast: |
Webcast – Biofrontera Inc. 3Q25 Results Conference Call |
About Biofrontera Inc.
Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the development and treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz ® with the RhodoLED ® lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and X.
Investor Relations
Ben Shamsian
Lytham Partners
646-829-9701
[email protected]
